Daclatasvir is a potent antiviral agent primarily used in the treatment of chronic hepatitis C virus (HCV) infection. It functions as an NS5A inhibitor, disrupting viral replication by targeting the HCV NS5A protein, which plays a critical role in viral RNA replication and assembly. It is effective against multiple HCV genotypes, particularly genotype 1 and 3. The compound is commonly administered in combination with other antiviral agents such as sofosbuvir, with or without ribavirin, depending on the patient’s condition and genotype. This combination therapy has shown high cure rates, often exceeding 90%, and is associated with shorter treatment durations compared to older regimens. Daclatasvir-based therapies are especially beneficial for patients with advanced liver disease, including those with cirrhosis, and have been used successfully in both treatment-naïve and treatment-experienced individuals. It also plays a role in treating HCV in special populations, such as those co-infected with HIV or patients who have undergone liver transplantation. Due to its high potency, favorable safety profile, and oral bioavailability, daclatasvir has become a key component in modern direct-acting antiviral regimens, contributing significantly to global efforts in eliminating hepatitis C.